China Coronavirus Cases Up Sharply As Pharma Rushes To Aid
Kaletra Finding Off-Label Use
Executive Summary
AbbVie’s HIV therapy Kaletra is now being used by the Chinese government to treat coronavirus-infected patients after a respiratory expert endorsed its use, while other pharma companies from Bayer to Innovent are showering support as China battles its worst virus outbreak since the SARS epidemic 17 years ago.
You may also be interested in...
China Offers Level Field In Trade Pact Bid But Multiple Pharma Barriers Remain
China has signaled that it will offer a more level playing field to foreign players as part of a bid to join a major regional trade pact but some see the gesture as offering little real relief and high hurdles remain.
China Hits Two Billion COVID Jabs But More Effective mRNA Shots Elude
Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.
Emerging Biopharma’s Next First Launch Market: China?
Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states.